
Stanford’s James Zou deploys 10,000 agentic “scientists” to run drug discovery end-to-end
A hierarchical AI lab simulates discovery, safety, and trial design while keeping full project context alive between steps.

Curating from trusted global sources…
Curated from trusted global sources, refined into briefing-grade analysis with executive summaries, insights, and bullet-point takeaways.

A hierarchical AI lab simulates discovery, safety, and trial design while keeping full project context alive between steps.

A faster chip-development sprint and a full-stack ambition means decision-makers should watch who controls AI costs and compute.

The company’s 2029 target turns a data-center bet into a valuation signal for investors and boardrooms.

A $1 billion deal moves private equity deeper into Japan’s long-term care market, with lasting implications for operators and investors.

HarbourView Equity Partners takes the publisher’s share of select Wolf Cousins songs, while Warner Chappell keeps administration.

A market slump knocked down Elon Musk’s wealth and raises fresh questions for boards tied to volatile tech cycles.

The satellite and rocket company’s quick $25 billion borrowing move signals how it plans to finance scale after going public.

On Thursday, Accenture hit its biggest one-day drop on record after forecasting worries that AI could hollow out consulting.

CNBC says SpaceX’s shares surge following its IPO Friday, forcing investors to reprice what “space” and “AI” are worth.

Big IPO, bigger options debut: what it means for investors, risk teams, and anyone benchmarking market appetite.

SpaceX exercised its option for Cursor in an all-stock deal worth $60 billion, reshaping AI dealmaking expectations.

The valuation jump of $1T in a single day changes the reference point for risk capital and public-market comps.